10.43
-0.17 (-1.60%)
新闻情绪
AIStockmoo 评分
| 价值 30% | -2.5 |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 负债低。盈利能力弱。短期流动性充足。现金流为负。 参考 | |
| 资本回报低于资本成本。资本回报下降。 参考 | |
| 时机 30% | -3.4 |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 过去一年没有明确趋势。股价远低于52周高点。 参考 | |
| 股价与均线呈空头排列。主要均线向下。接近下降的均线。低于长期均线,因此不给正面评分。 参考 | |
| 近期出现看跌反转形态:看跌吞没。 参考 | |
| 低于中期趋势线。 参考 | |
| 市场情绪 20% | 0.0 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻好坏参半或中性。 参考 | |
| 聪明钱 20% | -0.9 |
| 内部人士近期净买入。股价低于内部人士的买入价。 参考 | |
| 机构在最新13F申报中净-1.83%的股份:88家增持,79家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化-6.6%,回补天数18.8天(FINRA)。 参考 | |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 股价低于其52周平均水平。5年来上涨。 参考 | |
| 短期动能上升。 参考 | |
| 股价处于支撑位与阻力位之间。 参考 | |
| 最终评分 | -2.70 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Corvus Pharmaceuticals, Inc. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| CRVS | - | - | - | 4.31 |
| TRML | 1 B | - | - | 4.76 |
| CTMX | - | - | - | 1.56 |
| GANX | - | - | - | 4.54 |
| SRRK | - | - | - | 31.23 |
| IRON | - | - | - | 5.11 |
|
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 3.83% |
| 机构持股比例 | 48.27% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Adams Street Partners Llc | 30 Sep 2026 | 3,275,616 |
| Deep Track Capital, Lp | 30 Sep 2026 | 2,491,939 |
| Foresite Capital Management Vi Llc | 30 Sep 2026 | 1,831,233 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| ARCARA JEFFREY | 11.19 | - | 4,500 | 50,360 |
| 累积净数量 | 4,500 | |||
| 累积净值 ($) | 50,360 | |||
| 累积平均购买 ($) | 11.19 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| ARCARA JEFFREY | 职员 | 13 Nov 2026 | 买 (+) | 1,003 | 10.64 | 10,672 |
| ARCARA JEFFREY | 职员 | 12 Nov 2026 | 买 (+) | 497 | 10.62 | 5,278 |
| ARCARA JEFFREY | 职员 | 11 Nov 2026 | 买 (+) | 3,000 | 11.47 | 34,410 |
机构
机构持股比例: 86.31%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 88 | 6,554,089 |
| 减持 | 79 | 8,031,042 |
| 新建仓 | 29 | 2,064,545 |
| 清仓 | 18 | 2,124,893 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 17,759,451 | 18.8 |
| 15 Oct 2026 | 17,967,756 | 14.9 |
| 30 Sep 2026 | 17,797,751 | 13.3 |
| 15 Sep 2026 | 17,180,341 | 18.2 |
| 31 Aug 2026 | 19,017,840 | 29.6 |
| 14 Aug 2026 | 19,127,098 | 22.5 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 09 Nov 2026 | Yahoo Finance |
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2026… |
| 06 Nov 2026 | Yahoo Finance |
Corvus (CRVS) Q3 2026 Earnings Call Transcript
Soquelitinib's expanding pipeline spans lymphoma, eczema, skin disease and asthma. |
| 06 Nov 2026 | Yahoo Finance |
Corvus Pharmaceuticals Inc (CRVS) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Key ...
Corvus Pharmaceuticals Inc (CRVS) reported a $20.3 million net loss but holds $202.9 million in cash to fund operations into Q2 2028, with pivotal socolitinib data readouts expected through 2027… |
| 06 Nov 2026 | Yahoo Finance |
Corvus Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
Moby summary of Corvus Pharmaceuticals, Inc.'s Q3 2026 earnings call… |
| 05 Nov 2026 | Yahoo Finance |
What Corvus Pharmaceuticals (CRVS) Said on Its Q3 Earnings Call
Corvus Pharmaceuticals (NASDAQ:CRVS) reported a wider third-quarter loss as spending on clinical trials increased, while executives outlined a series of 2027 milestones for its lead experimental drug, soquelitinib. The company reported a net loss of $20.3 million for the third quarter of 2026, comp… |
| 05 Nov 2026 | Yahoo Finance |
Corvus: Q3 Earnings Snapshot
(AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Corvus Pharmaceuticals Inc. |
| 05 Nov 2026 | Yahoo Finance |
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results
Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Angel Pharmaceuticals completes enrollment in cohort 1 of Phase 1b/2 atopic dermatitis trial; topline data anticipated in March 2027 Phase 1b… |
| 04 Nov 2026 | Yahoo Finance |
Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition
Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) Safety profile consistent with results from soquelitinib T cell lymphoma and atopic… |
| 29 Oct 2026 | Yahoo Finance |
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTSOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on… |
| 30 Sep 2026 | Yahoo Finance |
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
Clinical trial designed to demonstrate proof-of-concept for soquelitinib in the treatment of hidradenitis suppurativa and evaluate its effects on Th17 biologySOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage… |
| 25 Sep 2026 | Yahoo Finance |
Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?
Corvus Pharmaceuticals (CRVS) has drawn fresh attention after recent trading left the biotech down about 19% over the past month and 13% over the past 3 months from a US$11.80 close. That recent slide sits against a much stronger ride for Corvus Pharmaceuticals, with the share price return still up… |
| 03 Sep 2026 | Yahoo Finance |
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat… |
| 27 Aug 2026 | Yahoo Finance |
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment Highlights… |
| 显示更多 | ||
近期信号 K线形态与EMA交叉
技术形态 中期
AI 技术分析
投资组合